Scarica l'app Stockscreener
1.635
4.14%
0.065
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
SpringWorks Therapeutics (SWTX) Continues Strong Yearly Run, Showing Over 29% YTD Gain - Daily Chhattisgarh News
Stellantis (NYSE:STLA) Receives Consensus Rating of “Hold” from Analysts - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of “Buy” by Analysts - Defense World
Pharmaceutical Stocks Worth Watching – June 13th - Defense World
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance
Gain Therapeutics to Participate in Upcoming Investor Conferences - Bluefield Daily Telegraph
Gain Therapeutics Opens Access to Management: CEO Featured at Two Major Biotech Investor Conferences - Stock Titan
Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share (NASDAQ:AQST) - Seeking Alpha
Telix Pharmaceuticals (ASX:TLX) Gains Portugal Approval for Illuccix in Prostate Cancer Detection - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - sharewise
Northern Trust Corp Raises Holdings in Banco Bradesco S.A. (NYSE:BBDO) - Defense World
Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Northern Trust Corp Has $226,000 Position in LightPath Technologies, Inc. (NASDAQ:LPTH) - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Purchased by Northern Trust Corp - Defense World
i-80 Gold Corp. (NYSE:IAUX) Receives $3.50 Average PT from Brokerages - Defense World
Northern Trust Corp Increases Stock Holdings in PetMed Express, Inc. (NASDAQ:PETS) - Defense World
Northern Trust Corp Purchases 10,466 Shares of United-Guardian, Inc. (NASDAQ:UG) - Defense World
Northern Trust Corp Grows Stock Holdings in Bridger Aerospace Group Holdings, Inc. (NASDAQ:BAER) - Defense World
Northern Trust Corp Increases Stock Position in NeueHealth, Inc. (NYSE:NEUE) - Defense World
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models - Yahoo Finance
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting - The Manila Times
Gain Therapeutics, Inc. Announces Oral Presentation at GBA1 Meeting 2025 in Montreal - Nasdaq
Gain Therapeutics' Chief Medical Officer Set to Reveal Latest GBA1 Therapeutic Developments in Montreal - Stock Titan
Gain Therapeutics Files $100 Million Mixed Shelf - marketscreener.com
Gain Therapeutics (GANX) Pursues $100 Million Securities Offerin - GuruFocus
Gain Therapeutics (GANX) Pursues $100 Million Securities Offering | GANX Stock News - GuruFocus
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings - Benzinga
CytomX Therapeutics Inc’s (CTMX) 4.41% Gain Is A Reason To Reconsider. - Stocksregister
HC Wainwright Brokers Increase Earnings Estimates for GANX - Defense World
Gotham Asset Management LLC Sells 176,437 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Buy” by Analysts - Defense World
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright - Defense World
Gain Therapeutics (GANX) Maintains 'Buy' Rating with $8 Price Ta - GuruFocus
Roth Capital Predicts Reduced Earnings for Gain Therapeutics - Defense World
Gain Therapeutics Reports Q1 2025 Financial Results - TipRanks
Gain Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gain (GANX) Advances Parkinson's Treatment in Phase 1b Trials | - GuruFocus
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update - The Manila Times
Gain Therapeutics, Inc. Reports Q1 2025 Financial Results and Corporate Update, Highlights Progress in Parkinson’s Disease Drug Development - Nasdaq
Gain Therapeutics' Parkinson's Drug Shows Promise: Key Biomarker Data Coming Mid-2025 - Stock Titan
Zevra Therapeutics Q1 Net Loss Narrows, Revenue Rises; Shares Gain After Hours - marketscreener.com
Crude Oil Gains 3%; US Inflation Eases In April - Benzinga
Gain Therapeutics (GANX) Showcases Promising Parkinson's Treatme - GuruFocus
Gain Therapeutics, Inc. Presents New Evidence for GT-02287 as Potential Disease-Modifying Therapy for Parkinson’s Disease at IAPRD 30th World Congress - Nasdaq
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - The Manila Times
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders - TradingView
Gain Therapeutics (GANX) Expected to Announce Earnings on Tuesday - Defense World
Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
TG Therapeutics, Inc. (TGTX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Gaining Ground: Verve Therapeutics Inc (VERV) Closes Lower at 5.95, Down -11.33 - DWinneX
Closing Figures Unveiled: Indaptus Therapeutics Inc (INDP) Gain 7.96, Closes at 0.71 - DWinneX
Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX
GANXGain Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results - Yahoo Finance
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):